About odyssey therapeutics inc - ODTX
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.
ODTX At a Glance
Odyssey Therapeutics, Inc.
51 Sleeper Street
Boston, Massachusetts 02210
| Phone | 1-617-865-9628 | Revenue | 2.98M | |
| Industry | Biotechnology | Net Income | -148,647,000.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ODTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ODTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.012 |
ODTX Liquidity
| Current Ratio | 7.201 |
| Quick Ratio | 7.201 |
| Cash Ratio | 6.85 |
ODTX Profitability
| Gross Margin | -65.02 |
| Operating Margin | -5,415.188 |
| Pretax Margin | -5,026.008 |
| Net Margin | -4,994.859 |
| Return on Assets | -61.83 |
| Return on Equity | -85.516 |
| Return on Total Capital | -61.325 |
| Return on Invested Capital | -75.079 |
ODTX Capital Structure
| Total Debt to Total Equity | 12.593 |
| Total Debt to Total Capital | 11.185 |
| Total Debt to Total Assets | 9.863 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 9.035 |